Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

This phase II trial tests how well tafasitamab, lenalidomide and venetoclax work in treating patients with mantle cell lymphoma that has come back (after a period of improvement) (relapsed) or that has not responded to previous treatment (refractory). Tafasitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Lenalidomide is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (Bcl-2) inhibitors. It may stop the growth

Trial Details

NCT ID
NCT05910801
Phase
PHASE2
Sponsor
Academic and Community Cancer Research United
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Biopsy
  • Biospecimen Collection
  • Bone Marrow Aspiration
  • Bone Marrow Biopsy
  • Computed Tomography
  • Lenalidomide
Locations (sample)
  • Rochester, Minnesota, United States|44.02163,-92.4699
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Age \>= 18 years old
  • Confirmed pathology diagnosis of mantle cell lymphoma (MCL) with t(11;14)(q13;q32) translocation or cyclin D1 overexpression NOTE: Patients with re…
  • Relapsed or refractory disease, which is defined as patients with \>= 1 line of prior systemic treatment NOTE: Prior exposure to lenalidomide or ve…
  • In the view of the treating physician, the patient is in need of treatment, for example, with lymphoma-related symptoms or cytopenia

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →